Table 3.

Summary of outcomes in the study cohort.

Full cohort	Control (n = 63)	Bowel rest (n = 28)	p-value
Composite outcome within 30 days	12 (19.0 [10.2–30.9])	4 (14.3 [4.0–32.7])	0.768
All-cause mortality	9 (14.3 [6.7–25.4])	3 (10.7 [2.3–28.2])	0.749
Recurrence of CDI	3 (4.8 [1.0–13.3])	1 (3.6 [0.10–18.3])	1.000
Switching of metronidazole to vancomycin	10 (15.9 [7.9–27.3])	2 (7.1 [0.90–23.5])	0.331

Matched cohort	Control (n = 23)	Bowel rest (n = 23)	p-value
Composite outcome within 30 days	4 (17.4 [5.0–38.8])	4 (17.4 [5.0–38.8])	1.000
All-cause mortality	3 (13.0 [2.8–33.6])	3 (13.0 [2.8–33.6])	1.000
Recurrence of CDI	1 (4.3 [0.10–21.9])	1 (4.3 [0.10–21.9])	1.000
Switching of metronidazole to vancomycin	6 (26.1 [10.2–48.4])	1 (4.3 [0.10–21.9])	0.096

Data are number (% [95% confidence interval]).

CDI, Clostridioides difficile infection.